Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Polymorphic hydroxylation of Debrisoquine in man.

Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL.

Lancet. 1977 Sep 17;2(8038):584-6.

PMID:
71400
2.
3.

The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population.

Islam SI, Idle JR, Smith RL.

Xenobiotica. 1980 Nov;10(11):819-25.

PMID:
7467397
4.

A study of the debrisoquine hydroxylation polymorphism in a Nigerian population.

Mbanefo C, Bababunmi EA, Mahgoub A, Sloan TP, Idle JR, Smith RL.

Xenobiotica. 1980 Nov;10(11):811-8.

PMID:
7467396
5.

Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.

Chapman PH, Rawlins MD, Shuster S, Idle JR, Ritchie JC, Smith RL.

Eur J Clin Pharmacol. 1981;21(3):257-8. No abstract available.

PMID:
6895622
6.

3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Zhen Y, Slanar O, Krausz KW, Chen C, Slavík J, McPhail KL, Zabriskie TM, Perlík F, Gonzalez FJ, Idle JR.

Drug Metab Dispos. 2006 Sep;34(9):1563-74. Epub 2006 Jun 16.

7.

The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method.

Kallio J.

Int J Clin Pharmacol Ther Toxicol. 1990 May;28(5):223-6.

PMID:
2163994
8.

Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.

Alván G, Grind M, Graffner C, Sjöqvist F.

Clin Pharmacol Ther. 1984 Oct;36(4):515-9.

PMID:
6478737
9.

[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].

Dick B, Küpfer A, Molnàr J, Braunschweig S, Preisig R.

Schweiz Med Wochenschr. 1982 Jul 24;112(30):1061-7. German.

PMID:
7123181
10.

Diurnal effects on debrisoquine hydroxylation phenotyping.

Lee EJ.

Eur J Clin Pharmacol. 1988;35(4):441-2.

PMID:
3197754
11.

Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry.

Meese CO, Fischer C, Eichelbaum M.

Biomed Environ Mass Spectrom. 1988 Jan 15;15(2):63-6. Erratum in: Biomed Environ Mass Spectrom 1988 Jun 1;15(11):635.

PMID:
3349209
12.

Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.

Kallio J, Lindberg R, Huupponen R, Iisalo E.

Br J Clin Pharmacol. 1988 Dec;26(6):791-5.

13.

[Hydroxylation of debrisoquin in Parkinson's disease].

Meillard MN, Bentué-Ferrer D, Brunet-Bourgin F, Morel G, Allain H.

Presse Med. 1990 May 19;19(20):947-9. French.

PMID:
2141131
14.

Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.

Sommers DK, Moncrieff J, Avenant J.

Hum Toxicol. 1988 May;7(3):273-6.

PMID:
3391625
15.
16.

Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.

Allen JG, East PB, Francis RJ, Haigh JL.

Drug Metab Dispos. 1975 Sep-Oct;3(5):332-7.

PMID:
241613
17.

Debrisoquine hydroxylation phenotype in SLE patients.

Seideman P, Alván G.

Scand J Rheumatol. 1989;18(1):63-4. No abstract available.

PMID:
2704985
18.

Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Dalén P, Dahl M, Andersson K, Bertilsson L.

Br J Clin Pharmacol. 2000 Feb;49(2):180-4.

19.

Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population.

Xu XM, Jiang WD.

Zhongguo Yao Li Xue Bao. 1990 Sep;11(5):385-8.

20.

Liquid chromatographic assay for debrisoquine and 4-hydroxydebrisoquine in urine.

Westwood BE, Harman PJ, Mashford ML.

J Chromatogr. 1986 Jan 10;374(1):200-3. No abstract available.

PMID:
3949930
Items per page

Supplemental Content

Write to the Help Desk